ThromboGenics eye drug cleared for U.S. launch

Summary:ThromboGenics has said that health regulators have approved eye treatment Jetrea for use in the United States.

ThromboGenics has said that health regulators have approved eye treatment Jetrea for use in the United States, Reuters reports.

The Belgian biopharmaceutical company says that the U.S. Food and Drug Administration (FDA) has cleared the drug -- previously only used in two multi-center trials conducted in the U.S. and Europe involving 652 patients -- to treat symptomatic vitreomacular adhesion.

Symptomatic vitreomacular adhesion is an aging-related condition where the vitreous gel of an eye adheres to the retina abnormally. Once an eye ages, the vitreous often separates from the retina, but if it is abnormal, this can result in pulling on the retina that can cause loss or distortion of vision.

Currently, the only treatment is surgical, and Jetrea is the first drug aimed at tacking the condition non-evasively.

Founded in 1991, the firm hopes that now it has been given permission to enter the U.S. market, profits can once again be secured -- as ThromboGenics last made a substantial profit in 2008 after developing a cancer-fighting antibody.

ThromboGenics plans to launch Jetrea in the United States in January 2013.

This post was originally published on Smartplanet.com

Topics: Innovation

About

Charlie Osborne, a medical anthropologist who studied at the University of Kent, UK, is a journalist, freelance photographer and former teacher. She has spent years travelling and working across Europe and the Middle East as a teacher, and has been involved in the running of businesses ranging from media and events to B2B sales. Charli... Full Bio

zdnet_core.socialButton.googleLabel Contact Disclosure

Kick off your day with ZDNet's daily email newsletter. It's the freshest tech news and opinion, served hot. Get it.

Related Stories

The best of ZDNet, delivered

You have been successfully signed up. To sign up for more newsletters or to manage your account, visit the Newsletter Subscription Center.
Subscription failed.